Trials / Unknown
UnknownNCT03855358
A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)
A Phase Ib Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of PD-L1 inhibitorin in combination with Anlotinib treatment for patients with triple receptor negative breast cancer treated after failure of standard therapy (including Anthracyclines and/or Taxanes).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2450 Injection and Anlotinib Hydrochioride Capsules | TQB2450 1200mg intravenously (IV) every-3-weeks (Q3W) and Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent |
Timeline
- Start date
- 2019-05-09
- Primary completion
- 2020-06-30
- Completion
- 2020-12-30
- First posted
- 2019-02-26
- Last updated
- 2019-10-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03855358. Inclusion in this directory is not an endorsement.